Novo Nordisk B A/S
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Novo Nordisk B A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
/ 
Novo Nordisk A/S is a Danish multinational pharmaceutical company specialising in treatments for diabetes, obesity, and other severe chronic diseases. Founded in 1923 and headquartered in Bagsværd, Denmark, the company is one of the largest producers of insulin and a global leader in diabetes care.
Its product portfolio includes insulin, GLP-1 receptor agonists, and related devices for managing diabetes, as well as medicines for obesity, haemophilia, and growth disorders. Novo Nordisk has played a significant role in advancing therapies for metabolic diseases and continues to expand research into cardiovascular and rare conditions.
The company operates production facilities in several countries, with key research and development centres located in Denmark, the United States, China, the United Kingdom and India. Its medicines are marketed in more than 170 countries.
Novo Nordisk is listed on the Nasdaq Copenhagen stock exchange and also has American Depositary Receipts (ADRs) traded on the New York Stock Exchange (NYSE).
